(To make an analogy here, these strategies are similar to those used to target KRAS-driven cancers: while some investigators have focused on directly inhibiting oncogenic KRAS, with the recently developed Kras (G12C) inhibitor AMG510 as a notable example (Canon et al., 2019), others have aimed instead to target KRAS-associated vulnerabilities, for example, the efforts to identify synthetically lethal interactions with KRAS (Cox et al., 2014)). Here, KRAS is linked to cancer.